Morgan Stanley Assumes Alector at Underweight, Lowers Price Target of $1.5
Alector Analyst Ratings
Morgan Stanley Maintains Alector(ALEC.US) With Sell Rating, Maintains Target Price $1.5
Morgan Stanley Initiates Alector(ALEC.US) With Sell Rating, Announces Target Price $1.5
BofA Securities Maintains Alector(ALEC.US) With Sell Rating
Alector (ALEC) Receives a Sell From Bank of America Securities
Alector Analyst Ratings
H.C. Wainwright Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $7
BTIG Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $5
Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Kura Oncology (KURA) and CareDx (CDNA)
William Blair Initiates Alector(ALEC.US) With Buy Rating
Analysts Conflicted on These Healthcare Names: Alector (ALEC) and US Physical Therapy (USPH)
TD Cowen Maintains Alector(ALEC.US) With Buy Rating
BTIG Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $5
Alector's Strategic Advancements and Promising Pipeline: A Buy Rating by Thomas Shrader
BTIG Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $5
BTIG Remains a Buy on Alector (ALEC)
BofA Securities Maintains Alector(ALEC.US) With Sell Rating, Maintains Target Price $1
Sell Rating on Alector Due to Delays in Key Data Releases and Low Market Cap
Alector Downgraded to Neutral From Outperform at Mizuho